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Background: Determination of fetal aneuploidy is central to evaluation of recurrent pregnancy loss (RPL). However,
obtaining this information at the time of a miscarriage is not always possible or may not have been ordered. Here
we report on “rescue karyotyping”, wherein DNA extracted from archived paraffin-embedded pregnancy loss tissue
from a prior dilation and curettage (D&C) is evaluated by array-based comparative genomic hybridization (aCGH).
Methods: A retrospective case series was conducted at an academic medical center. Patients included had
unexplained RPL and a prior pregnancy loss for which karyotype information would be clinically informative but
was unavailable. After extracting DNA from slides of archived tissue, aCGH with a reduced stringency approach was
performed, allowing for analysis of partially degraded DNA. Statistics were computed using STATA v12.1 (College
Station, TX).
Results: Rescue karyotyping was attempted on 20 specimens from 17 women. DNA was successfully extracted in
16 samples (80.0%), enabling analysis at either high or low resolution. The longest interval from tissue collection to
DNA extraction was 4.2 years. There was no significant difference in specimen sufficiency for analysis in the
collection-to-extraction interval (p = 0.14) or gestational age at pregnancy loss (p = 0.32). Eight specimens showed copy
number variants: 3 trisomies, 2 partial chromosomal deletions, 1 mosaic abnormality and 2 unclassified variants.
Conclusions: Rescue karyotyping using aCGH on DNA extracted from paraffin-embedded tissue provides the
opportunity to obtain critical fetal cytogenetic information from a prior loss, even if it occurred years earlier. Given
the ubiquitous archiving of paraffin embedded tissue obtained during a D&C and the ease of obtaining results
despite long loss-to-testing intervals or early gestational age at time of fetal demise, this may provide a useful
technique in the evaluation of couples with recurrent pregnancy loss.
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Recurrent pregnancy loss (RPL) is a common though
poorly understood condition. Defined as two or more
failed clinical pregnancies, RPL affects up to 5% of cou-
ples attempting to conceive [1,2]. In addition to the
physical burdens, RPL is often an emotionally and psy-
chologically difficult diagnosis for these women and their
partners. Diagnosing the cause of a pregnancy loss is* Correspondence: zev.williams@einstein.yu.edu
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unless otherwise stated.important both to determine whether further interven-
tions are indicated, as well as to provide a sense of clos-
ure to the patient and her partner.
Chromosomal abnormalities account for up to 75% of
first trimester pregnancy losses [3-10]. Given this high
frequency, a critical initial step in the evaluation of re-
current pregnancy loss is to perform cytogenetic ana-
lysis of the products of conception (POCs) in order to
determine whether aneuploidy was the cause of the loss.
If the pregnancy loss was due to aneuploidy, then the
likelihood of recurrence returns to the age-adjusted
baseline, which increases with advancing maternal agel Ltd. This is an Open Access article distributed under the terms of the Creative
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work-up is indicated.
Traditionally, cytogenetic evaluation following a preg-
nancy loss is performed via Giemsa staining of meta-
phase spreads. This requires culturing cells obtained
from freshly collected chorionic villi, and so POCs must
be promptly placed in appropriate culture media before
cell death occurs. These requirements create many situa-
tions in which conventional karyotyping may not be
feasible. Examples include when the pregnancy loss oc-
curred a significant time before the POCs could be
placed in appropriate culture media (e.g. patients with a
lengthened interval between the demise and the time of
tissue collection or when tissue is passed at home or at
a location where culturing could not be started), when
there may not be the necessary culture media or situ-
ational awareness required to send the material for
karyotyping (e.g. in the case of emergent dilation and
curettage (D&C)) or when samples are lost in transit,
become infected, or fail to grow during culture.
Due to the high likelihood of aneuploidy in cases of
sporadic pregnancy loss, current recommendations by
the American College of Obstetrics and Gynecology as
well as the American Society for Reproductive Medicine
are to obtain karyotype results only after the second or
third loss [12]. Recent cost-analyses have supported this
recommendation [13,14]. Thus, the POCs from a first or
second loss are often not sent for karyotyping, even fol-
lowing a D&C. However, if the patient goes on to have
subsequent losses, particularly at earlier gestations pre-
cluding successful genomic analysis, the karyotypes from
the earlier miscarriage would be informative. Therefore,
there is a need to establish a standardized method for
retrospectively retrieving cytogenetic information from
previous pregnancy losses in a robust manner that could
be readily employed in a clinical laboratory.
In the context of freshly collected POCs, array-based
comparative genomic hybridization (aCGH) may be equally
or even more informative than conventional karyotyping
[15-23]. When used in prenatal diagnosis and the evalu-
ation of children with developmental delay, aCGH allows
for the detection of copy number variants (CNVs) such as
deletions and insertions with a 10-fold increased resolution
compared with traditional karyotyping [24-27].
Unlike prior approaches that required PCR amplifi-
cation of extracted genomic DNA [28], an automated
approach has successfully been utilized in tumor geno-
typing and cytogenetic analysis in oncology. In these
cases, aCGH analysis of DNA extracted from paraffin-
embedded tumor samples is frequently used, demon-
strating the distinct advantage that this technology
does not require live cells [29]. Here we sought to
extend this approach to analysis of paraffin embedded
POCs.For the purpose of retrospectively or “rescue” karyo-
typing, we adapted aCGH analysis of DNA extracted
from paraffin embedded tissue, a technique widely used
in analysis of tumor samples, to analysis of paraffin em-
bedded POCs. This technique provides the potential to
obtain detailed cytogenetic information from previously
collected paraffin-embedded conceptual tissue. Based on
our findings, we propose this technique as a method of
obtaining useful cytogenetic information for patients
who require karyotype results but have had either no
attempts or failed attempts at conventional karyotyping
at the time of prior losses.
Methods
Patient selection
This was a retrospective case series carried out at an
academic medical center. Patients received care under
the auspice of the Program for Early and Recurrent
Pregnancy Loss (PEARL) at the Albert Einstein College
of Medicine, Bronx NY, and were included if they had
RPL and had an indication for karyotyping of a prior loss
for which traditional cytogenetic evaluation was either
not attempted or was unsuccessful. All patients who met
these criteria during the study period were included. In
each case, the cost of testing was covered by the patient’s
insurance. At the time when the pregnancy loss was diag-
nosed, gestational age was estimated using fetal biometry.
Patients underwent D&C or MVA at the discretion of the
provider. The research was reviewed and exempted by the
Institutional Review Board (2013-2212).
Tissue collection
In each case, DNA was extracted from twenty slides of
5 μM thickness obtained from the original paraffin em-
bedded blocks produced for routine pathology examin-
ation to confirm POC samples at the time of the original
D&C. If DNA was of sufficient quality and quantity, aCGH
analysis was performed on high-resolution arrays. This ap-
proach enables the detection of CNVs as small as 1 Kb
(average 7.5 Kb). However, for purposes of detecting sim-
ple aneuploidy (the most likely genetic cause for preg-
nancy loss), such high resolution is not necessary and so if
DNA was of poorer quality or quantity (<500 ng measured
by Qubit® fluorometric analysis, Life Technologies) a lower
resolution analysis was performed. This low resolution
analysis could detect CNVs of 17 Kb, 100-fold smaller
than the range that would be needed to diagnose cases
of aneuploidy.
DNA extraction
A slide from the formalin-fixed paraffin-embedded (FFPE)
block was reviewed by a pathologist and the area of fetal
tissue circled. Fetal or chorionic villus cells were macro-
dissected from this circled area to reduce maternal cell
Kudesia et al. Reproductive Biology and Endocrinology 2014, 12:19 Page 3 of 8
http://www.rbej.com/content/12/1/19contamination (MCC) and subjected to DNA extraction
using the QIAamp FFPE DNA extraction kit (Qiagen,
Valencia, CA). The gDNA concentration was measured
using Nanodrop 1000 (Fisher, Waltham, Massachusetts)
and requantified by Qubit 2.0 Fluorometer (Life tech-
nologies, Carlsbad, CA).
aCGH
Cases were run on 2 × 400 K CGH arrays (Agilent Tech-
nologies) for high resolution testing. Where DNA was in-
sufficient for high resolution testing, cases with less than
300 ng DNA were run on 4 × 180 K CGH array (Agilent
Technologies) for low-resolution testing. Five hundred ng
genomic DNA from patients and the reference were
digested with AluI and RsaI (Invitrogen) for 2 hours at
37°C and labeled using Agilent enzymatic labeling kit
according to manufacturer’s instructions. Patient and
reference DNA were labeled with Cy5 and Cy3, respect-
ively. Unincorporated nucleotides were removed using
Amicon Ultra-0.5 30 K filter column (Millipore, Billerica,
MA). Patient DNA and reference DNA were co-hybridized
to arrays for 40 hours at 65°C in a rotator (Agilent
Technologies) at 20 rpm. The arrays were then washed
with Agilent wash buffer and scanned using an Agilent
Microarray Scanner. Scanned data from aCGH was ex-
tracted using Feature Extraction (version 10.10; AgilentTable 1 Baseline demographic and clinical background inform





1 1 30/31 G2P0020 6
2 2 26/27 G7P2052 16
3 2 26/27 G7P2052 20
4 3 33/33 G5P0050 8
5 4 26/24 G4P1030 7
6 5 34/36 G14P3-0-11-3 8
7 5 34/36 G14P3-0-11-3 18
8 6 36/36 G8P3053 11
9 7 31/35 G9P4054 8
10 8 22/22 G2P0020 8
11 9 35/36 G10P3073 8
12 10 40/38 G3P0030 9
13 11 28/29 G9P2072 17
14 12 30/30 G9P3063 10
15 13 45/43 G10P1091 7
16 14 37/39 G7P3043 8
17 15 46/46 G13P6258 7
18 16 30/33 G3P0030 8
19 16 30/33 G3P0030 6
20 17 36/35 G4P0040 10
Abbreviations: NA not available, SP spontaneous passage, D&C dilation and curettagTechnologies). Extracted data was analyzed using Agilent
Genomic Workbench (version 7.0; Agilent Technologies)
and Agilent CytoGenomics (version 2.0; Agilent Technolo-
gies). Genomic copy number changes were identified
using Aberration Detection Method 1 (ADM-1), an al-
gorithm implemented in Genomic Workbench (Agilent
Technologies) and visual evaluation. If MCC was sus-
pected based on results, it was reported as such. In
cases where testing was performed for MCC, a rate of
approximately 5% was noted, which would be unlikely
to impact array results. Testing is validated in-house
with known positives and negatives. These methods
have been previously reported [21,30].
Statistical analysis
Statistical evaluation was performed using STATA v12.1
(College Station, TX). It was determined a priori that to
detect a 60% success rate in rescue karyotyping in our
sample compared to the reported values of 85% or greater
in the largest studies [24,25], with α = 0.05 and 80% power,
at least 20 specimens were needed. Descriptive statistics
were computed, and are presented as mean ± SD for
normally-distributed and median [inter-quartile range
(IQR)] for non-normally-distributed continuous data;
categorical data are presented as n (%). Bivariate ana-



























e, MVA manual vacuum aspiration.
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squared and Fisher’s exact tests for categorical data.Results
Demographics
Seventeen women, providing 20 samples, met criteria over
a 12-month period (Table 1). The median maternal age
was 33 [30-36], while the median paternal age was 35 [30-
36]. The median gravity was 7 [4-9], and the median parity
was 2 [0-3]. Of these specimens, the median gestational
age at the time of the pregnancy loss was 8 weeks [7-10].
Among the 17 women, 13 (76.5%) had multiple losses
without any prior karyotype performed, while 4 (23.5%)
had had cytogenetic evaluation of at least a single prior
loss. Three patients in the latter category had prior trad-
itional karyotyping attempts that had been unsuccessful,
due to failed growth in culture or being lost in transport.Table 2 aCGH results






(Qubit) ng/ul DLRS Su
1 13 1000 1.97 161 0.3
2 12 1000 1.92 85 0.42
3 15 500 2.02 28.6 0.47
4 13 250 2.03 10.4 0.45
5 15 1000 1.99 83 0.67
6 13 550 1.91 23 0.33
7 35 800 2.01 47.8 0.28
8 14 1000 21.93 446 0.28
9 2
10 2
11 9 220 1.98 26.6 0.71
12 9 460 1.62 14.9 0.7
13 47 1000 1.9 154 0.26
14 27 600 2.01 41.8 0.4
15 40 1000 1.91 92 0.34
16 37 1000 2.05 94.2 0.32
17 41 300 1.9 15.7 0.31
18 30 1.99 56.4
19 1
20 50 750 1.88 48.4 0.44
Abbreviations: DLRS Distribution of Log2 Ratio Spread, CNV copy number variant, HR
contamination, T13 Trisomy 13.Of the 20 specimens, information regarding the inter-
val between diagnosis of demise and tissue collection
was available for 9 (45.0%) specimens; of these, the median
interval was 2 days [0-2]. One specimen (5.0%) was passed
spontaneously, while 16 (80.0%) were from a D&C and 3
(15.0%) from manual vacuum aspiration (MVA).
aCGH testing outcome
Eleven specimens (55.0%) were run at full resolution
without difficulty (Table 2). If sufficient DNA for trad-
itional analysis was not available, lower-resolution test-
ing was performed. Five (25.0%) samples were run at
low resolution; and 4 samples (20.0%) were insufficient
for evaluation. In all, results were generated for the ma-
jority of cases, 16 of 20 (80.0%).
The longest duration between documented loss of fetal
cardiac activity and collection of tissue that resulted in a
successful karyotype analysis was 14 days, though thisfficiency aCGH results aCGH interpretation
HR arr (1-22,X) x2 Euploid female
HR
arr (1-22,X) x2, gain 70Kb at
1q42.13, loss 230Kb at 3q27.2
Female with unclassified CNV
LR arr (1-22,X) x2 Euploid female
LR arr (1-22,X) x2 Euploid female
HR
arr (1-22,X)x2, gain 660Kb at
5q13.1, gain 330Kb at 5q32




Male with mosaic deletion
including Williams syndrome
chromosome region
HR arr (1-22) x2, (XY) x1 Euploid male
HR arr (1-22,X) x2 Euploid female
I - Insufficient fetal tissue
I - Insufficient fetal tissue
LR
arr (1-12,14-22) x2, mos (13) x3,
mos (X) x2, mos (Y) x1
MCC in T13 male v. vanished
T13 female twin v. chimeric
pregnancy v. true mosaic
LR arr (1-20,22,X) x2 (21) x3 Female with Trisomy 21
HR arr (1-22,X) x2 Euploid female




Female with Trisomy 18




Male with Trisomy 11
I - Insufficient fetal tissue





Male with unbalanced 4p-5q
translocation; known paternal
paracentric inversion
high-resolution, LR low-resolution, I insufficient, MCCmaternal cell
Figure 1 (See legend on next page.)
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Figure 1 Selected Array CGH Results. (A) Specimen 12. Red arrow shows gain of a copy of chromosome 21. (B) Specimen 11. Red arrows
show mosaic gains of chromosome 13 and chromosome X, green arrow shows a mosaic loss of chromosome Y (a female reference DNA was
used in this case). (C-E) Specimen 20. C shows the whole genome view of this unbalanced translocation, with the green arrow showing a partial
loss of 4p and the red arrow showing a partial gain of 5q. D shows a whole chromosome view of chromosome 4 with a normal case adjacent for
comparison to highlight the partial loss of 4p, seen where the DNA signal (in blue) deviates leftward. E shows a chromosome view of chromosome 5,
also with a normal case adjacent for comparison, to highlight the partial gain in 5q where the DNA signal (in blue) deviates rightward.
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is often inaccurate due to unknown time of fetal demise.
The longest duration between collection of tissue and
DNA extraction that resulted in a successful karyotype
analysis was 4.2 years (1562 days).
Of the 16 specimens that had sufficient DNA for
aCGH analysis, 8 (50.0%) were euploid, and 8 (50.0%)
showed copy number variants potentially responsible for
the pregnancy loss (Table 2, Figure 1). While an instance
of trisomy likely explains a loss, the clinical significance
of other findings, such as unclassified CNVs, remains to
be determined. As a general rule, the significance will
correlate with the amount of genomic material included,
and the number and significance of the genes within that
locus. The three non-mosaic trisomies were all from
cases where the maternal age was 40 years or greater.
DNA quality data
The DNA integrity, including both quality and quantity,
was reflected by the array QC metrics, Distribution of
Log2 Ratio Spread (DLRS) (Table 2). Three cases (18.75%)
with DLRS <0.3 were listed as “good”; 10 cases (62.5%)
with DLRS between 0.3 and 0.5 were listed as “poor”; and
3 (18.75%) with DLRS >0.5 as “very poor”. The mean
DLRS was 0.42 ± 0.16.
Predictors of aCGH success
Comparing those samples found to be sufficient for high-
resolution aCGH, sufficient for low-resolution aCGH or
insufficient, there was no difference in the median gesta-
tional age at time of pregnancy loss (8 [7-16] v 9 [8-10] v 8Table 3 Specimen characteristics by test outcome
Insufficient





Demise to Collection (days) 1, n = 1
Collection to Extraction (days) 239 [162-1770]
Extraction to Reporting (days) 2 [1.5-16]
Abnormal Finding -
Abbreviations: D&C dilation and curettage, MVAmanual vacuum aspiration, SP spont[7,8], respectively), p = 0.32 (Table 3). Similarly, there was
no significant difference between the median interval be-
tween specimen collection and time to processing
(114 days [63-264] v 313 days [229-545] v 239 days [162-
1770], respectively), p = 0.14. Nor were there any signifi-
cant differences in the method of obtaining the tissue
(p = 0.59), the median interval between demise and col-
lection (p = 0.33) or the percentage of abnormal findings
(p > 0.99). Insufficient results were reported faster than tests
generating results at low- or high-resolution (p = 0.03).
Discussion
Rescue karyotyping using aCGH on DNA extracted from
paraffin embedded tissue provided clinically relevant fetal
cytogenetic information in 80% of patients who had under-
gone either failed or no attempts at conventional karyotyp-
ing in prior losses. Though most of these abnormalities
could be detected with conventional karyotyping, when
that testing is unavailable for any reason, rescue karyo-
typing provides a critical alternative method to uncover
the genomic information. While other technologies,
such as fluorescence in situ hybridization (FISH), quan-
titative fluorescence polymerase chain reaction (QF-PCR),
and sub-telomeric multiplex ligation-dependent probe
amplification have been utilized for genetic evaluation,
these methods only assay targets designated a priori,
and not the entire genome. Microdissection of chori-
onic villi from a single slide followed by whole genome
amplification (WGA) is technically challenging and not
amenable to routine application in a clinical laboratory
setting [28].Low-resolution High-resolution p
9 [8-10] 8 [7-16] 0.32
0.59
3 (60%) 9 (81.8%)
2 (40%) 1 (9.1%)
0 (0%) 1 (9.1%)
0 [0-2], n = 3 2 [2-7], n = 5 0.33
313 [220-545] 114 [63-264] 0.14
13 [9-15] 35 [13-41] 0.03
2 (40%) 6 (54.6%) >0.99
aneous passage.
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critical fact that unlike conventional karyotyping, aCGH
testing can be performed from paraffin embedded tissue
blocks that are routinely prepared and archived follow-
ing a D&C as part of standard hospital protocol. The
process requires minimal effort from the provider, aside
from procuring these slides and getting them sent for
testing at a qualified center. As such, once protocols
have been established for coordinating the movement of
specimen slides from the original facility to the testing
facility and for communicating the results to the ordering
physician, the process is quite simple. This simplicity lends
itself to the possibility of increased utilization in patients
with RPL.
aCGH is also able to detect smaller copy number vari-
ants compared to traditional karyotyping, and other stud-
ies have already established a higher pickup rate with
aCGH. In a recent study by Reddy et al. aCGH yielded
results more often than traditional karyotyping (87.4%
v 70.5%, p < 0.001) and provided better detection of aneu-
ploidy or pathogenic copy-number variants (8.3 v 5.8%,
p = 0.007) [25]. Despite the small number in this case
series, our success rate at obtaining results is on par with
these results, and we have been able to utilize this technol-
ogy to obtain genomic information that would otherwise
not have been available. More widespread use of this tech-
nology may expand our knowledge about CNV associated
with unexplained RPL. This could provide insights to both
patients and providers, and may also hone our precision
in using pre-implantation genetic diagnosis and screening
methods to assist these patients in completing euploid
pregnancies. This information can be helpful in determin-
ing whether a more extensive and costly RPL evaluation is
necessary and may also provide a definitive explanation
for a pregnancy loss for those patients who require it.
However, CNVs of undetermined clinical significance can
also be discovered and these may not play a causal role in
the miscarriage.
Though current institutional rates for traditional karyo-
typing is $820, and microarray testing $1600-1750 de-
pending on resolution, this cost disparity only underscores
the utility of it as described here, as a rescue method when
traditional testing fails or is not performed. Further, we
anticipate the cost for microarray testing to continue to
fall as technology advances, while the cost of traditional
G-band karyotyping will likely remain constant or even
increase due to labor costs. Additionally, the patient’s
insurance typically covers microarray testing in this
context; this was the case for all of the patients in our
cohort. In summary, aCGH testing holds potential for
cost-effective use in rescue karyotyping by enabling
cytogenetic evaluation of archived fetal tissue. This can
provide physicians and patients with clinically relevant
cytogenetic information on prior pregnancy losses. Theresults of this testing can help guide a physician’s deci-
sion to pursue a RPL evaluation and can provide sense
of closure to patients.
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